BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

902 related articles for article (PubMed ID: 28152543)

  • 21. MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1.
    Lin ZY; Huang YQ; Zhang YQ; Han ZD; He HC; Ling XH; Fu X; Dai QS; Cai C; Chen JH; Liang YX; Jiang FN; Zhong WD; Wang F; Wu CL
    Int J Cancer; 2014 Aug; 135(3):541-50. PubMed ID: 24382668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression.
    Hughes RM; Simons BW; Khan H; Miller R; Kugler V; Torquato S; Theodros D; Haffner MC; Lotan T; Huang J; Davicioni E; An SS; Riddle RC; Thorek DLJ; Garraway IP; Fertig EJ; Isaacs JT; Brennen WN; Park BH; Hurley PJ
    Cancer Res; 2019 Jul; 79(14):3636-3650. PubMed ID: 31123087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence.
    Nordby Y; Richardsen E; Rakaee M; Ness N; Donnem T; Patel HR; Busund LT; Bremnes RM; Andersen S
    Sci Rep; 2017 Feb; 7():43378. PubMed ID: 28233816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of T cell immunoglobulin mucin-3 in prostate cancer.
    Piao YR; Piao LZ; Zhu LH; Jin ZH; Dong XZ
    Asian Pac J Cancer Prev; 2013; 14(6):3897-901. PubMed ID: 23886204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stromal expression of MiR-21 predicts biochemical failure in prostate cancer patients with Gleason score 6.
    Melbø-Jørgensen C; Ness N; Andersen S; Valkov A; Dønnem T; Al-Saad S; Kiselev Y; Berg T; Nordby Y; Bremnes RM; Busund LT; Richardsen E
    PLoS One; 2014; 9(11):e113039. PubMed ID: 25401698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of two WFDC1/ps20 isoforms in prostate stromal cells induces paracrine apoptosis through regulation of PTGS2/COX-2.
    Hickman OJ; Smith RA; Dasgupta P; Rao SN; Nayak S; Sreenivasan S; Vyakarnam A; Galustian C
    Br J Cancer; 2016 May; 114(11):1235-42. PubMed ID: 27115470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling.
    Tuxhorn JA; Ayala GE; Smith MJ; Smith VC; Dang TD; Rowley DR
    Clin Cancer Res; 2002 Sep; 8(9):2912-23. PubMed ID: 12231536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches.
    Özdemir BC; Hensel J; Secondini C; Wetterwald A; Schwaninger R; Fleischmann A; Raffelsberger W; Poch O; Delorenzi M; Temanni R; Mills IG; van der Pluijm G; Thalmann GN; Cecchini MG
    PLoS One; 2014; 9(12):e114530. PubMed ID: 25485970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy.
    Nordby Y; Andersen S; Richardsen E; Ness N; Al-Saad S; Melbø-Jørgensen C; Patel HR; Dønnem T; Busund LT; Bremnes RM
    Prostate; 2015 Nov; 75(15):1682-93. PubMed ID: 26268996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples.
    Gravina GL; Mancini A; Ranieri G; Di Pasquale B; Marampon F; Di Clemente L; Ricevuto E; Festuccia C
    Int J Oncol; 2013 Jun; 42(6):2116-22. PubMed ID: 23589051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
    Benko G; Spajić B; Krušlin B; Tomas D
    Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Asporin Is a Fibroblast-Derived TGF-β1 Inhibitor and a Tumor Suppressor Associated with Good Prognosis in Breast Cancer.
    Maris P; Blomme A; Palacios AP; Costanza B; Bellahcène A; Bianchi E; Gofflot S; Drion P; Trombino GE; Di Valentin E; Cusumano PG; Maweja S; Jerusalem G; Delvenne P; Lifrange E; Castronovo V; Turtoi A
    PLoS Med; 2015 Sep; 12(9):e1001871. PubMed ID: 26327350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-β signaling proteins.
    Zou A; Lambert D; Yeh H; Yasukawa K; Behbod F; Fan F; Cheng N
    BMC Cancer; 2014 Oct; 14():781. PubMed ID: 25344051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?
    Carozzi F; Tamburrino L; Bisanzi S; Marchiani S; Paglierani M; Di Lollo S; Crocetti E; Buzzoni C; Burroni E; Greco L; Baldi E; Sani C
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):201-12. PubMed ID: 26210155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome.
    Tidehag V; Hammarsten P; Egevad L; Granfors T; Stattin P; Leanderson T; Wikström P; Josefsson A; Hägglöf C; Bergh A
    Eur J Cancer; 2014 Jul; 50(10):1829-1835. PubMed ID: 24726733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Podoplanin expression identified in stromal fibroblasts as a favorable prognostic marker in patients with colorectal carcinoma.
    Yamanashi T; Nakanishi Y; Fujii G; Akishima-Fukasawa Y; Moriya Y; Kanai Y; Watanabe M; Hirohashi S
    Oncology; 2009; 77(1):53-62. PubMed ID: 19556810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alterations in the methylome of the stromal tumour microenvironment signal the presence and severity of prostate cancer.
    Lawrence MG; Pidsley R; Niranjan B; Papargiris M; Pereira BA; Richards M; Teng L; Norden S; Ryan A; Frydenberg M; Stirzaker C; Taylor RA; Risbridger GP; Clark SJ
    Clin Epigenetics; 2020 Mar; 12(1):48. PubMed ID: 32188493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
    Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
    Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.
    Fritzsche FR; Jung M; Tölle A; Wild P; Hartmann A; Wassermann K; Rabien A; Lein M; Dietel M; Pilarsky C; Calvano D; Grützmann R; Jung K; Kristiansen G
    Eur Urol; 2008 Nov; 54(5):1097-106. PubMed ID: 18061337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
    Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
    Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.